Surveillance of MRSA, ESBL-producing Klebsiella pneumoniae, carbapenem-resistant Enterobacteriaceae, and Clostridioides difficile in Catalan Hospitals: Findings from the VINCat Program.

INTRODUCTION

This study aimed to describe the epidemiological trends of methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae, carbapenem-resistant Enterobacteriaceae (CRE), and Clostridioides difficile in Catalonia, Spain.

METHODS

We analyzed data from hospitals participating in the VINCat Program from 2008 to 2022. The study analyzed antimicrobial susceptibility data from isolates collected in acute care hospital settings. Key metrics: annual MRSA rate, incidence density of new MRSA cases, MRSA bacteremia, and hospital-acquired MRSA cases. We assessed the rate of ESBL-producing K. pneumoniae and carbapenemase-resistant (CR)-K. pneumoniae, CR-Enterobacter cloacae, and CR-Escherichia coli. For C. difficile infections (CDI), the incidence density was determined.

RESULTS

While MRSA rate slightly decreased over the study period, the incidence of MRSA bacteremia increased. Global hospital-acquired MRSA incidence decreased but increased in small hospitals. Among patients with bacteremia, the rate of ESBL-producing K. pneumoniae remained stable; in contrast, the rate of CR-K. pneumoniae rose in large centers as well as did the rates of CR-E. cloacae and CR-E. coli. CDI incidence rose substantially over the study period.

CONCLUSION

VINCat's hospital surveillance system has provided valuable insights into the evolving incidence of key multidrug-resistant organisms and CDI. These findings highlight the need for targeted interventions, particularly for MRSA in smaller hospitals and for CR-Enterobacteriaceae and CDI across all hospital sizes.